NEW YORK (GenomeWeb News) – Affymetrix today said that that it has penned a five-year gene-expression collaboration with the Peter MacCallum Cancer Centre in Australia.
Terms of the agreement call for Peter Mac researchers to use Affymetrix GeneChip technology for translational research projects. The first studies will cover ovarian cancer and carcinoma of unknown primaries.
Millennium Science will supply Peter Mac with Affy’s technology and provide technical support.
Financial details of the deal were not disclosed.